Setidegrasib Shows Promise for KRAS G12D-Driven Solid Tumors

A global phase 1 clinical trial of the investigational drug setidegrasib has demonstrated early promise in treating aggressive lung and pancreatic cancers driven by the KRAS G12D mutation. The study establishes targeted protein degradation as a viable new approach for treating these specific solid tumors, according to research published online by Nature Medicine on April 14, 2026.

Setidegrasib, previously known as ASP3082, is a first-in-class KRAS degrader. Unlike traditional inhibitors that attempt to block the signaling of a protein, setidegrasib is designed to tag and destroy the cancer-causing protein produced by the KRAS G12D mutation.

The trial was led by Wungki Park, MD, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center (MSK). Results from the study were published in the New England Journal of Medicine in March 2026, providing the first data on the drug’s use in humans.

A New Mechanism for Targeted Therapy

The drug utilizes a method known as targeted protein degradation, employing proteolysis-targeting chimeras, or PROTACs. This approach represents a shift from small-molecule inhibition. Regarding the function of the drug, Dr. Park stated that rather than blocking the signal, setidegrasib removes the KRAS protein itself.

The KRAS G12D mutation is a significant driver in several aggressive cancers. It is present in approximately 40% of pancreatic ductal adenocarcinomas and about 5% of non-small cell lung cancers (NSCLC). While other KRAS subtypes, such as KRAS G12C, have already seen the approval of targeted agents, no approved targeted therapies had existed for the G12D variant prior to this research.

Clinical Outcomes in Lung and Pancreatic Cancers

The phase 1 trial evaluated the safety and clinical activity of setidegrasib in patients with advanced tumors that had progressed after prior treatments. The results indicated benefit and a generally manageable safety profile for both cancer types.

For patients with metastatic lung cancer, the trial found that approximately one-third responded to the treatment. These responses showed encouraging durability, and about 60% of the lung cancer patients in the study were alive after one year.

The outcomes for pancreatic cancer patients, who often face more limited treatment options, were as follows:

• Approximately 25% of pancreatic cancer patients responded to the drug.
• The median overall survival for this group was 10 months.
• Two-thirds of the pancreatic cancer patients in the trial had already stopped responding to two other lines of treatment before enrolling in the study.

Overcoming Structural Challenges

The KRAS G12D mutation has historically been difficult to target therapeutically. The success of previous KRAS G12C inhibitors was largely due to a specific structural opportunity: a mutant cysteine residue that allowed for covalent binding.

Because the G12D variant lacks this specific chemical opportunity, it remained therapeutically elusive for years. The use of a protein degrader like setidegrasib bypasses the need for the same type of covalent binding required by inhibitors, providing a way to attack the mutation directly.

The data from this first-in-human study provides evidence of target degradation and demonstrates that KRAS G12D can be therapeutically attacked in patients rather than only in laboratory models or hypotheses.

While these early results mark a potential shift in the understanding of what is druggable in solid tumors, researchers note that these findings do not yet establish a new standard of care. Setidegrasib remains an investigational drug, and further study is required to fully determine its long-term efficacy and safety.